This is a mobile optimized page that loads fast, if you want to load the real page, click this text.

ARX - Aroa Biosurgery

Jump to new
quarterly out, 3 days of drops from $0.80 and now as low as $0.58

FINANCIAL HIGHLIGHTS
• Positive cash flows from operations of NZ$1.2 million during the quarter, reflecting the first quarter of positive cash flow since admission to the ASX in July 2020.
• Total cash on hand increased by NZ$0.3 million, ending the quarter with a strong cash balance of NZ$21.9 million.
• Strong cash receipts from customers of NZ$19.5 million during the quarter, in line with expectations.
• Net cash outflow from investing activities was NZ$0.8 million for the quarter, primarily reflecting routine capital expenditure.
• Full-year FY25 guidance (on a reported basis), is expected to be NZ$81-84 million total revenue (a 17-22% increase on FY24) and a normalised EBITDA profit of NZ$2-4 million.

OPERATIONAL HIGHLIGHTS
• The first peer reviewed study to emerge from the Company’s larger ‘MASTRR’ study was published in December. The real-world limb salvage study found Myriad Matrix™ and Myriad Morcells™ achieved tissue fill and coverage within 30 days with just one application and no complications. The findings of the study reinforce the efficacy of Myriad™ products in complex limb salvage procedures.
• AROA direct sales are now contributing 56% of the year-to-date sales mix, with Myriad expected to continue growing, becoming a larger part of the overall sales mix
• Regulatory approval received for Endoform™ and Myriad Matrix in Lebanon, Endoform in Vietnam, and Myriad in Saudi Arabia.
 
ouch... clearly the punters were expecting more developments....will it repair itself?
 
Now cashflow positive and moving towards profitability.
Looking for a short term bounce.
 
Quarterly out on 29th of Feb
• Positive cash flows from operations of NZ$1.2 million during the quarter, reflecting the first quarter of positive cash flow since admission to the ASX in July 2020.
• Total cash on hand increased by NZ$0.3 million, ending the quarter with a strong cash balance of NZ$21.9 million.
• Strong cash receipts from customers of NZ$19.5 million during the quarter, in line with expectations.
• Net cash outflow from investing activities was NZ$0.8 million for the quarter, primarily reflecting routine capital expenditure.
• Full-year FY25 guidance (on a reported basis), is expected to be NZ$81-84 million total revenue (a 17-22% increase on FY24) and a normalised EBITDA profit of NZ$2-4 million.

YTD
 
Quite positive about this....
Surprised it is not performing better but then again not much makes sense to me recently.
 
Seems to be a simple supply & demand issue, TOO MANY SELLERS , on my Brokerage account, i see all the buys & sells, some others don't ? as far as i know. There are too many people been trying/ sitting on a Sell price .55c +++, the stock hasn't traded above that barely past 2 months.
trading at about .44c, i'm looking at buying nearly 1/2 the shares soon at around .21c Average at this rate !!!! People just in to the seller's, it'll be at 1/2 the price at the high it reached .80c
It's all PSYCHOLOGY !!!
 
Not sure how you are going to do that?


I topped up and am hoping the tariff issue does not affect this stock too much,
 
I Hope i don't, but i'm TRYING to support the stock ARX. I account for half the quantity of stocks on the BUY, 210K, as of today, an old trick I seen on other stocks, check out CCX, if you can see the full market depth, 6.2 million at a buy of .001 & .002 cents, i'm sure they aren't waiting for another GFC, even if, the stock would'nt sink that low i doubt.
Just making use, i hope of cash reserves.I will have exit those buy's eventually, the seller's do come in during the day,i've watched this stock, and others closely. But punters will push a stock down if less buyer's around, even if and especially when RSI is heading WELL South of 30% as a basic Metric.
 
@mullokintyre

A singularly unsuccessful tip for the CY2025 competition. There has been nothing announced since late Jan, and the SP is falling away ever since. What will the next Quarterly update bring?
 
Hopefully it is lack of Invester interest rather than inside knowledge.

(My order got filled.... Not overly confident. )
 
a steady retracement as per my cunning plan to stand out in the CY2025 tipping comp @mullokintyre

has been as low as $0.35 this year

.
Not much news; quarterly out on Tuesday 29th ..and that will be my May update?
 
$0.47

FY25 Results
• Total revenue of NZ$84.7 million (23% growth on FY24), exceeding guidance of $81-84 million.
• NZ$32.3 million in Myriad™ product revenue (38% growth on FY24).
• NZ$39.7 million in total OviTex™/ OviTex™ PRS product revenue (22% growth on FY24).
• Product gross margin of 86%.
• Normalised EBITDA profit of NZ$4.2 million (up from NZ$3.1 million normalised EBITDA loss in FY24), exceeding guidance of NZ$2 - 4 million.
• Achieved positive operating cash flow in H2 FY25, with cashflows from operations of NZ$2.3 million for H2 FY25.
• Strong cash balance of NZ$22.0 million with no debt.

FY26 Outlook
• Total revenue guidance of NZ$92-100 million (10 - 20% growth on FY25 on a constant currency basis), primarily driven by growth in Myriad sales, and continued investment in sales productivity. Myriad sales are expected to grow in excess of 25%. Sales to TELABio are conservatively estimated to grow at a more moderate pace.
• Normalised EBITDA of NZ$5-8 millioniv (19 - 90% growth on FY25), reflecting restrained clinical expenses and investment in new product development.
 
This month's post for the yearly Comp @mullokintyre

another sideways month


FY26 Guidance ​
NZ$92 -100m Total Revenue
(YoY CC growth 10 – 20%), Myriad 25%+

NZ$5-8m - Normalised EBITDA
 
Hmmm @63c is actually up 10%
 
This month's post for the yearly Comp @mullokintyre

SP showing a slow incremental stability - there have been no announcements in September to move it along
 
You must log in or register to reply here.

Similar threads

TTX - Tetratherix Limited
Replies
4
Views
1K
Dona Ferentes
OCC - Orthocell Limited
2 3
Replies
51
Views
15K
Dona Ferentes
AVH - AVITA Medical, Inc
3 4 5
Replies
86
Views
29K
Dona Ferentes
Menu
Log in
Register
Cookies are required to use this site. You must accept them to continue using the site. Learn more...